ArticleJournal of extracellular vesicles2020
Extracellular vesicles from plasma have higher tumour RNA fraction than platelets.
Article in Journal of extracellular vesicles, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 39 citations in OpenAlex.
- Extracellular vesicles in targeted drug delivery: from biological functions to surface engineering.Molecular biomedicine · 2026Review
- MiRNA-based expression signatures in differential diagnosis of enchondroma and chondrosarcoma.Journal of bone oncology · 2026Article
- Blood-based tumor biomarkers: integrating biological layers and analytical strategies for precision cancer detection.Frontiers in medicine · 2026Review
- A promising frontier of circulating messenger RNA in liquid biopsy: From mechanisms to clinical applications.International journal of cancer · 2025Review
- Liquid biopsy as a potential tool for diagnosis and clinical monitoring of cutaneous and uveal melanoma.The journal of liquid biopsy · 2025Review
- Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives.European journal of medical research · 2025Review
- Microfluidic Liquid Biopsy Minimally Invasive Cancer Diagnosis by Nano-Plasmonic Label-Free Detection of Extracellular Vesicles: Review.International journal of molecular sciences · 2025Review
- Extracellular vesicles as biomarkers and drug delivery systems for tumor.Acta pharmaceutica Sinica. B · 2025Review
- The Potential of Extracellular Vesicle-Mediated Spread of Self-Amplifying RNA and a Way to Mitigate It.International journal of molecular sciences · 2025Article
- Stoichiometric constraints for detection of EV-borne biomarkers in blood.Journal of extracellular vesicles · 2025Review
- Investigating the role of exosomal long non-coding RNAs in drug resistance within female reproductive system cancers.Frontiers in cell and developmental biology · 2025Review
- Advances and potentials in platelet-circulating tumor cell crosstalk.American journal of cancer research · 2025Review
- Exosomes to exosome-functionalized scaffolds: a novel approach to stimulate bone regeneration.Stem cell research & therapy · 2024Review
- Characterizing the Cell-Free Transcriptome in a Humanized Diffuse Large B-Cell Lymphoma Patient-Derived Tumor Xenograft Model for RNA-Based Liquid Biopsy in a Preclinical Setting.International journal of molecular sciences · 2024Article
- Regulation of cargo selection in exosome biogenesis and its biomedical applications in cancer.Experimental & molecular medicine · 2024Review
- TEP RNA: a new frontier for early diagnosis of NSCLC.Journal of cancer research and clinical oncology · 2024Review
- Cancer diagnosis using label-free SERS-based exosome analysis.Theranostics · 2024Review
- Exploiting the biogenesis of extracellular vesicles for bioengineering and therapeutic cargo loading.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Review
- Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction.Journal of personalized medicine · 2023Review
- Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA.NAR cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In addition to Circulating Tumour Cells (CTCs), cell-free DNA (cfDNA) and Extracellular Vesicles (EVs), the notion of "Tumour-Educated Platelets" (TEP) has recently emerged as a potential source of tumour-derived biomarkers accessible through blood liquid biopsies. Here we sought to confirm the suitability of the platelet blood fraction for biomarker detection in comparison to their corresponding EV fraction. As publications have claimed that tumour RNA and other tumour-derived material are transferred from tumour cells to the platelets and that tumour-derived transcripts can be detected in platelets, we chose to focus on RNA carrying a mutation as being of bona fide tumour origin. After informed consent, we collected prospective blood samples from a cohort of 12 melanoma patients with tissue-confirmed BRAF V600E mutation. Each blood specimen was processed immediately post collection applying two published standard protocols in parallel selecting for EVs and platelets, respectively. The RNA of each fraction was analysed by a highly sensitive ARMS RT-qPCR enabling the quantification of the mutant allele fraction (%MAF) of BRAF V600E down to 0.01%. In a direct comparative analysis, the EV fraction contained detectable BRAF V600E in 10 out of 12 patients, whereas none of the patient platelet fractions resulted in a mutant allele signal. The platelet fraction of all 12 patients contained high amounts of wild-type BRAF signal, but no mutation signal above background was detectable in any of the samples. Our observations suggest that the phenomenon of tumour RNA transfer to platelets occurs below detection limit since even a very sensitive qPCR assay did not allow for a reliable detection of BRAF V600E in the platelet fraction. In contrast, EV fractions derived from the same patients allowed for detection of BRAF V600E in 10 of 12 blood specimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.